Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema [0.03%]
遗传性血管水肿长期预防治疗的药物疗法网络meta分析研究
Sarah Walsh,Meaghan Bartlett,Elizabeth M Salvo-Halloran et al.
Sarah Walsh et al.
Background and objectives: Several treatments for long-term prophylaxis (LTP) of hereditary angioedema (HAE) are in clinical use, such as garadacimab, lanadelumab, subcutaneous C1 esterase inhibitor (C1INH), and berotrals...
An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [0.03%]
富马酸艾拉曲韦和富马酸替诺福韦二吡美.drive对照治疗的探索性药物基因组学试点研究
Derek E Murrell,Benjamin C Kennard,Maria E Bertoni et al.
Derek E Murrell et al.
Background and objectives: The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each f...
Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis [0.03%]
评估denosumab生物类似药候选药物临床试验中抗SARS-CoV-2 IgG反应的分析（ singlicate分析）结果
Sandra Ribes,Natalia Krivtsova,Celine Schelcher et al.
Sandra Ribes et al.
Background and objectives: During the coronavirus disease-2019 (COVID-19) pandemic there was the uncertainty that the long-term immune response generated upon natural infection or triggered by available severe acute respi...
Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats [0.03%]
康泽唑尼（MRX-I）与利奈唑胺 Sprague-Dawley 大鼠的安全性评价
Liping Wei,Min Hong,Min Lu et al.
Liping Wei et al.
Background & objectives: Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infectio...
Bioequivalence and Safety of Two Amisulpride Formulations in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study [0.03%]
空腹及餐后条件下两种 amisulpride 制剂在中国健康志愿者体内的生物等效性与安全性：一项随机、开放标签、单次给药、两制剂交叉试验
Min Wang,Yu Peng,Hegui Yan et al.
Min Wang et al.
Background and objectives: Amisulpride is a second-generation antipsychotic drug that selectively binds to D2 and D3 dopaminergic receptors in the limbic system. In this study, the bioequivalence of an amisulpride formula...
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA) [0.03%]
在中国开展的两项III期研究（EGALITY和EQUIRA）中评估GP2015（依那西普类似药）治疗类风湿关节炎、银屑病或银屑病关节炎患者的有效性：患者报告的结果措施
Diamant Thaçi,Sascha Gerdes,Hendrik Schulze-Koops et al.
Diamant Thaçi et al.
Background and objective: GP2015 is an etanercept biosimilar. Equivalent efficacy and comparable safety of GP2015 to reference etanercept (ref-ETN) was demonstrated in two phase III studies, one in patients with moderate-...
Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug Therapy [0.03%]
西罗莫司血药浓度及其影响因素的分析：个体化用药的启示
Xiaolin Xu,Xueting Mao,Bo Liu et al.
Xiaolin Xu et al.
Background and objective: The purpose of this study is to investigate the status of blood concentration of sirolimus (SRL), explore the factors influencing SRL drug blood concentration, and provide guidance for the approp...
Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar [0.03%]
替扎木单抗与赫赛汀相似性药代动力学和药效学桥接研究的临床前评估研究报告
Herve Bischoff,Neil K O&#x;Connor,Jamie Kim et al.
Herve Bischoff et al.
Introduction: The high cost of trastuzumab (Herceptin®) limits its accessibility for patients worldwide. Biosimilars, such as Tuznue® (HD201), represent a promising alternative to improve access to this essential therap...
Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases [0.03%]
氟喹诺酮类药物自发报告系统中的不良反应及临床常规病例中不良反应的事后分析研究
Diana Dubrall,Julia Wicherski,Maike Below et al.
Diana Dubrall et al.
Introduction: In November 2018, the European Medicines Agency (EMA) restricted the use of fluoroquinolones (used by mouth, injections or inhalation) in the context of a referral due to long-lasting and potentially irrever...
A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database [0.03%]
α葡萄糖苷酸在FDA不良事件报告系统（FAERS）数据库的现实世界数据分析
Yi Yin,Jie Jiang,Youpeng Jin
Yi Yin
Background and objective: Alglucosidase alfa for injection is used as an enzyme replacement therapy for the treatment of Pompe disease. The safety profile of alglucosidase alfa-associated adverse events requires a compreh...